| Primary information |
|---|
| ID | antitb_1330, |
| Name | 23029305 |
| N-Terminal modification | Human beta casein fragment (54-59) |
| C-Terminal Modification | VEPIPY |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Linear |
| Nature | 6 |
| Source | L |
| Origin | Cationic |
| Species | Protein derived |
| Strain | Human beta casein protein |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 25μM |
| Inhibition Concentration | in vitro |
| Sequence | 2012 |
| Cytotoxicity | THP 1 cell lines |
| In vivo Model | Cells treated with 10 mM and 20 mM peptide showed 17.13% and 29.56% increase in clearance of BCG |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | Increase expression of IL-8, MCP-1, MIP-1β, TNF-α |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
Tertiary Structure
(Technique) | Not Predicted), |